Delaware Division of Public Health (DPH) is providing the following information to the medical community regarding the recommendation to defer administration of the meningococcal polysaccharide-protein conjugate vaccine (MCV4; Menactra) to children aged 11-12 years.
MCV4 was licensed in January 2005 for use among persons aged 11-55 years. The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination with MCV4 of persons aged 11-12 years, of adolescents at high school entry, and of college freshman living in dormitories. Vaccination is also recommended for other persons at increased risk for meningococcal disease such as military recruits, travelers to areas where meningococcal disease is endemic, laboratory workers and persons with terminal complement deficiency.
Sanofi Pasteur (manufacturer), anticipates that demand will outpace supply at least through summer 2006. Therefore, CDC, in consultation with ACIP, the American Academy of Pediatrics (AAP), American Academy of Family Physicians (AAFP), American College Health Association (ACHS), and Society for Adolescent Medicine, recommends providers continue to vaccinate adolescents at high school entry and college freshman living in dormitories. Other persons at high risk for meningococcal disease, as mentioned above, should also be vaccinated. Current supply will meet demand for these groups.
Until further notice, administration of MCV4 to persons aged 11-12 years should be deferred. These individuals should be tracked and recalled for vaccination when the supply improves.
CDC Meningococcal Vaccine Information Page: http://www.cdc.gov/nip/menus/vaccines.htm#mening